This article first appeared on GuruFocus .
Release Date: February 13, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Shaily Engineering Plastics Ltd ( BOM:501423 ) reported a strong revenue growth of 27% year-on-year, reaching 251 crores in Q3 FY26.
-
EBITDA increased by 43% year-on-year to 66 crores, with a margin expansion of 310 basis points to 26.5%.
-
The healthcare segment's revenue contribution doubled to 42%, indicating significant growth in this area.
-
The company is establishing a new scalable facility in Abu Dhabi for manufacturing pen and auto injectors, expected to be operational by Q4 FY28.
-
Shaily Engineering Plastics Ltd ( BOM:501423 ) has onboarded two new customers for GLP-1s and signed two new contracts with global pharma companies for pen injectors.
Negative Points
-
The consumer segment experienced a revenue decline of 13% year-on-year, reflecting challenges in this area.
-
There was a 12% decline in the volume of polymers processed in Q3 FY26 compared to the previous year.
-
Machine utilization remained flat at about 47.1%, indicating potential inefficiencies or underutilization.
-
The company faced delays in the qualification of new production lines, impacting the timeline for commercial production.
-
Increased administrative and selling expenses, partly due to exhibitions and setup costs in Abu Dhabi, affected margins.
Q & A Highlights
-
Warning! GuruFocus has detected 2 Warning Signs with BOM:501423.
-
Is BOM:501423 fairly valued? Test your thesis with our free DCF calculator.
Q: Can you provide an update on the new production lines and their operational status? A: The first production line is undergoing operational qualification and should be completed next week, with commercial production starting in March. The second line is expected to arrive by the end of April or beginning of May 2026 and will be commercialized by the end of July 2026. (Respondent: Managing Director)
Q: Are the new capacity expansions fully backed by contracts, and what is the expected utilization timeline? A: The capacity expansions in India are mostly backed by commercial contracts. The Abu Dhabi expansion is about 50-60% secure in terms of capacity commitments. We expect full utilization of the existing lines within 12 to 24 months. (Respondent: Managing Director)
Q: What is the status of the GLP-1 injector supply, and when can we expect a ramp-up? A: We have already started supplying GLP-1 injectors for commercial launches in several countries. However, we are currently facing challenges as our high-speed line is still under qualification. Once operational, we expect to meet the demand more effectively. (Respondent: Managing Director)
Q: Can you provide insights into the consumer electronics segment and its potential impact on margins? A: The consumer electronics opportunity is highly scalable and involves high complexity and precision, which limits competition. While margins won't match those of the healthcare segment, they are expected to be higher than our home furnishings business. (Respondent: Managing Director)
Q: How is the company addressing the pricing pressure in the GLP-1 market, and what are the expectations for future pricing trends? A: While there is some pricing pressure, it is not significant. We have seen a 10-15% price erosion on high-volume contracts, which is typical. We expect pricing to stabilize after the initial 24 months of supply. (Respondent: Managing Director)
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
